Identification

Name
Clonidine
Accession Number
DB00575  (APRD00174, DB07566)
Type
Small Molecule
Groups
Approved
Description

Clonidine, an imidazoline-derivative hypotensive agent is a centrally-acting α2-adrenergic agonist. It crosses the blood-brain barrier and acts in the hypothalamus to induce a decrease in blood pressure. It may also be administered as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone. Clonidine may be used for differential diagnosis of pheochromocytoma in hypertensive patients. Other uses for clonidine include prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD). Clonidine also exhibits some peripheral activity.

Structure
Thumb
Synonyms
  • 2-[(2,6-Dichlorophenyl)imino]imidazoline
  • 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
  • Chlofazoline
  • Clonidin
  • Clonidina
  • Clonidinum
External IDs
ST 155 / ST 155-BS
Product Ingredients
IngredientUNIICASInChI Key
Clonidine HydrochlorideW76I6XXF064205-91-8ZNIFSRGNXRYGHF-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CatapresTablet.2 mg/1OralBoehringer Ingelheim1999-05-01Not applicableUs
CatapresPatch, extended release.3 mg/24hTransdermalBoehringer Ingelheim1985-10-01Not applicableUs
CatapresTablet.1 mg/1OralRemedy Repack2016-10-07Not applicableUs
CatapresPatch, extended release.2 mg/24hTransdermalBoehringer Ingelheim1985-10-01Not applicableUs
CatapresTablet.3 mg/1OralBoehringer Ingelheim1999-05-01Not applicableUs
CatapresPatch, extended release.1 mg/24hTransdermalRebel Distributors1985-10-01Not applicableUs
CatapresTablet.1 mg/1OralBoehringer Ingelheim1999-05-01Not applicableUs
CatapresPatch, extended release.1 mg/24hTransdermalBoehringer Ingelheim1985-10-01Not applicableUs
Catapres Tab 0.1mgTablet0.1 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1973-12-312017-02-15Canada
Catapres Tab 0.2mgTablet0.2 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1974-12-312015-03-30Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clonidineTablet0.025 mgOralApotex Corporation2004-07-13Not applicableCanada
Apo-clonidine Tab 0.1mgTablet.1 mgOralApotex Corporation1990-12-31Not applicableCanada
Apo-clonidine Tab 0.2mgTablet.2 mgOralApotex Corporation1990-12-31Not applicableCanada
ClonidineInjection, solution500 ug/mLEpiduralFresenius Kabi2011-07-08Not applicableUs
ClonidinePatch.3 mg/dTransdermalPhysicians Total Care, Inc.2011-05-10Not applicableUs
ClonidinePatch.3 mg/dTransdermalMylan Pharmaceuticals2013-02-08Not applicableUs
ClonidinePatch, extended release.1 mg/24hTransdermalCorium International, Inc.2016-08-03Not applicableUs
ClonidineInjection, solution500 ug/mLEpiduralX Gen Pharmaceuticals, Inc.2013-10-29Not applicableUs
ClonidinePatch.2 mg/dTransdermalMylan Pharmaceuticals2013-02-08Not applicableUs
ClonidinePatch, extended release.2 mg/24hTransdermalLake Erie Medical Dba Quality Care Produts Llc2010-08-25Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clonidine HydrochlorideTablet.1 mg/1OralAlembic Pharmaceuticals Limited2016-05-03Not applicableUs
Clonidine HydrochlorideTablet.2 mg/1OralAlembic Pharmaceuticals Limited2016-05-03Not applicableUs
Clonidine HydrochlorideTablet.3 mg/1OralAlembic Pharmaceuticals Limited2016-05-03Not applicableUs
International/Other Brands
Catapres-TTS (Boehringer Ingelheim) / Catapresan (Boehringer Ingelheim) / Catapressan (Boehringer Ingelheim) / Dixarit (Boehringer Ingelheim) / Isoglaucon (Agepha) / Run Rui (Bausch & Lomb) / Velaril (Roemmers) / Winpress (Winston)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ClorpresClonidine Hydrochloride (.3 mg/1) + Chlorthalidone (15 mg/1)TabletOralMylan Pharmaceuticals1998-03-132018-02-28Us
ClorpresClonidine Hydrochloride (.1 mg/1) + Chlorthalidone (15 mg/1)TabletOralMylan Pharmaceuticals1998-03-132018-02-28Us
ClorpresClonidine Hydrochloride (.2 mg/1) + Chlorthalidone (15 mg/1)TabletOralMylan Pharmaceuticals1998-03-132018-02-28Us
Combipres 0.1/15 TabClonidine Hydrochloride (.1 mg) + Chlorthalidone (15 mg)TabletOralBoehringer Ingelheim (Canada) Ltd Ltee1974-12-311997-08-14Canada
Categories
UNII
MN3L5RMN02
CAS number
4205-90-7
Weight
Average: 230.094
Monoisotopic: 229.017352717
Chemical Formula
C9H9Cl2N3
InChI Key
GJSURZIOUXUGAL-UHFFFAOYSA-N
InChI
InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
IUPAC Name
N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine
SMILES
ClC1=CC=CC(Cl)=C1NC1=NCCN1

Pharmacology

Indication

May be used as an adjunct in the treatment of hypertension, as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone, for differential diagnosis of pheochromocytoma in hypertensive patients, prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD).

Structured Indications
Pharmacodynamics

Clonidine is an α-adrenergic agent that acts specifically on α2-receptors. α2-receptors regulate a number of signaling pathways mediated by multiple Gi proteins, Gαi1, Gαi2, and G&alphai3. Stimulation of α2-receptors mediates effects such as inhibition of adenylyl cyclase, stimulation fo phospholipase D, stimulation of mitogen-activated protein kinases, stimulation of K+ currents and inhibition of Ca2+ currents. Three G-protein coupled α2-receptor subtypes have been identified: α2A, α2B, and α2C. Each subtype has a unique pattern of tissue distribution in the central nervous system and peripheral tissues. The α2A-receptor is widely distributed throughout the central nervous system; it is found in the locus coeruleus, brain stem nuclei, cerebral cortex, septum, hypothalamus, and hippocampus. α2A-receptors are also expressed in the kidneys, spleen, thymus, lung and salivary glands. The α2C-receptor is primarily expressed in the central nervous system, including the striatum, olfactory tubercle, hippocampus and cerebral cortex. Low levels of the α2C-subtype are also found in the kidneys. The α2B-receptor is located primarily in the periphery (kidney, liver, lung and heart) with low levels of expression in the thalamic nuclei of the central nervous system. The α2A- and α2C-receptors are located presynaptically and inhibit the released of noradrenaline from sympathetic nerves. Stimulation of these receptors decreases sympathetic tone, resulting in decreases in blood pressure and heart rate. Sedation and analgesia is mediated by centrally located α2A-receptors, while peripheral α2B-receptors mediate constriction of vascular smooth muscle. α2A-Receptors also mediate essential components of the analgesic effect of nitrous oxide in the spinal cord. Clonidine stimulates all three α2-receptor subtypes with similar potency. Its actions in the nervous system decreases blood pressure in patients with hypertension and decreases sympathetic overactivity in patients undergoing opioid withdrawal. Clonidine is also a potent sedative and analgesic and can prevent post-operative shivering in intensive and post-operative care. Its use in differential diagnosis of pheochromocytoma owes to the fact that hypertension in patients with pheochromocytoma is refractory to antihypertensive treatment with clonidine.

Mechanism of action

See Pharmacology section above.

TargetActionsOrganism
AAlpha-2A adrenergic receptor
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
AAlpha-2C adrenergic receptor
agonist
Human
UAlpha-1A adrenergic receptor
agonist
Human
UAlpha-1B adrenergic receptor
agonist
Human
UAlpha-1D adrenergic receptor
agonist
Human
Absorption

Well absorbed following oral administration. Bioavailability following chronic administration is approximately 65%.

Volume of distribution
Not Available
Protein binding

20-40%, primarily to albumin

Metabolism

Hepatic. Metabolized via minor pathways. The major metabolite, p-hydroxyclonidine, is present in concentrations less than 10% of those of unchanged clonidine in urine. Four metabolites have been detected, but only p-hydroxyclonidine has been identified.

Route of elimination
Not Available
Half life

6-20 hours; 40-60% is excreted in urine unchanged, 20% is excreted in feces. Less than 10% is excreted by p-hydroxyclonidine.

Clearance
Not Available
Toxicity

Oral LD50 is 150 mg/kg in rat and 30 mg/kg in dog. Symptoms of overdose include constriction of pupils of the eye, drowsiness, high blood pressure followed by a drop in pressure, irritability, low body temperature, slowed breathing, slowed heartbeat, slowed reflexes, and weakness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clonidine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Clonidine.Experimental
AbirateroneThe serum concentration of Clonidine can be increased when it is combined with Abiraterone.Approved
AcebutololClonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clonidine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clonidine.Approved
AcetyldigitoxinClonidine may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
AcetyldigoxinClonidine may increase the atrioventricular blocking (AV block) activities of Acetyldigoxin.Experimental
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Clonidine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clonidine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Clonidine is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clonidine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Clonidine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Clonidine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Clonidine is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Clonidine.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Clonidine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Clonidine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clonidine.Approved, Illicit, Investigational
AlprenololClonidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanClonidine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineClonidine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Clonidine is combined with Amiloride.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Clonidine.Illicit, Withdrawn
AmiodaroneThe metabolism of Clonidine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clonidine.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Clonidine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clonidine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clonidine.Approved, Illicit
AmoxapineAmoxapine may decrease the antihypertensive activities of Clonidine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clonidine.Experimental
AmphetamineAmphetamine may increase the hypotensive activities of Clonidine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clonidine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Clonidine is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Clonidine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Clonidine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Clonidine.Approved, Investigational
ArotinololClonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Clonidine.Approved, Investigational
ArtemetherThe metabolism of Clonidine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Clonidine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clonidine.Approved
AtazanavirThe metabolism of Clonidine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololClonidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Clonidine can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Clonidine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clonidine.Investigational, Vet Approved
AzelastineClonidine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clonidine is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Clonidine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clonidine.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Clonidine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Clonidine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Clonidine.Approved
BefunololClonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Clonidine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clonidine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Clonidine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Clonidine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Clonidine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clonidine.Approved
Benzylpenicilloyl PolylysineClonidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Clonidine.Approved, Withdrawn
BeractantClonidine may increase the bradycardic activities of Beractant.Approved
BetaxololClonidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Clonidine.Approved
BevantololClonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BietaserpineClonidine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostClonidine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololClonidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BoceprevirThe metabolism of Clonidine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololClonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Clonidine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Clonidine can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Clonidine may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Clonidine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clonidine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Clonidine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Clonidine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clonidine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Clonidine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clonidine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Clonidine.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Clonidine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clonidine.Approved, Investigational, Withdrawn
BucindololClonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolClonidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Clonidine is combined with Bumetanide.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Clonidine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clonidine.Approved, Investigational
BupranololClonidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineClonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Clonidine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clonidine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clonidine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Clonidine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clonidine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Clonidine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clonidine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clonidine.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the hypertensive activities of Clonidine.Approved
CadralazineClonidine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineClonidine may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Clonidine can be decreased when combined with Caffeine.Approved
CalfactantClonidine may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.Approved
CandesartanClonidine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Clonidine is combined with Candesartan cilexetil.Approved
CandoxatrilClonidine may increase the hypotensive activities of Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Clonidine.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Captopril.Approved
CarbamazepineThe metabolism of Clonidine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Clonidine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Clonidine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonidine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Clonidine.Withdrawn
CarteololClonidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolClonidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Clonidine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololClonidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Clonidine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clonidine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clonidine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clonidine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clonidine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clonidine.Approved
ChloroquineThe metabolism of Clonidine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clonidine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clonidine.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clonidine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clonidine.Approved
CholecalciferolThe metabolism of Clonidine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineClonidine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clonidine.Approved, Investigational
CimetidineThe metabolism of Clonidine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Clonidine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clonidine.Approved, Vet Approved
CitalopramThe metabolism of Clonidine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Clonidine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Clonidine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clonidine is combined with Clidinium.Approved
ClobazamThe metabolism of Clonidine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Clonidine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clonidine.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Clonidine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonidine is combined with Clonazepam.Approved, Illicit
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Clonidine.Experimental
CloranololClonidine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clonidine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Clonidine.Experimental
ClotrimazoleThe metabolism of Clonidine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clonidine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Clonidine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Clonidine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clonidine.Approved, Illicit
ConivaptanThe serum concentration of Clonidine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Clonidine can be decreased when combined with Crizotinib.Approved
CryptenamineClonidine may increase the hypotensive activities of Cryptenamine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Clonidine.Approved
CyclopenthiazideClonidine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Clonidine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideClonidine may increase the hypotensive activities of Cyclothiazide.Approved
CymarinClonidine may increase the atrioventricular blocking (AV block) activities of Cymarin.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clonidine.Approved
Cyproterone acetateThe serum concentration of Clonidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Clonidine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Clonidine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clonidine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Clonidine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Clonidine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Clonidine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinClonidine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DeferasiroxThe serum concentration of Clonidine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilClonidine may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Clonidine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Clonidine.Investigational
DeserpidineClonidine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clonidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Clonidine.Approved
DeslanosideClonidine may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Clonidine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Clonidine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clonidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clonidine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clonidine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Clonidine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clonidine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Clonidine.Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Clonidine.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Clonidine.Experimental
diethylnorspermineClonidine may increase the hypotensive activities of diethylnorspermine.Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Clonidine is combined with Difenoxin.Approved, Illicit
DigitoxinClonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin.Approved, Investigational
DigoxinClonidine may increase the atrioventricular blocking (AV block) activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Clonidine may increase the atrioventricular blocking (AV block) activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineClonidine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clonidine.Approved, Illicit
DihydroergotamineThe metabolism of Clonidine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clonidine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clonidine.Experimental, Illicit
DiltiazemClonidine may increase the atrioventricular blocking (AV block) activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Clonidine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Clonidine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Clonidine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clonidine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Clonidine is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Clonidine.Experimental
DonepezilClonidine may increase the bradycardic activities of Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clonidine.Vet Approved
DorzolamideClonidine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Clonidine.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Clonidine is combined with Doxazosin.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Clonidine.Approved
DoxycyclineThe metabolism of Clonidine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Clonidine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Illicit
DronedaroneThe metabolism of Clonidine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clonidine.Experimental, Illicit
DuloxetineClonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clonidine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Clonidine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clonidine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Clonidine is combined with Efavirenz.Approved, Investigational
EfonidipineClonidine may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe metabolism of Clonidine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Clonidine.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Enalapril.Approved, Vet Approved
EnalaprilatClonidine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineClonidine may increase the hypotensive activities of Endralazine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clonidine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clonidine.Approved, Investigational
EnzalutamideThe serum concentration of Clonidine can be decreased when it is combined with Enzalutamide.Approved
EpanololClonidine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Eplerenone.Approved
EpoprostenolClonidine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Clonidine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Clonidine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Clonidine.Approved
ErythromycinThe metabolism of Clonidine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Clonidine.Investigational
EsmololClonidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clonidine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clonidine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid.Approved
EthanolClonidine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clonidine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Clonidine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clonidine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Clonidine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clonidine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clonidine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Clonidine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clonidine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clonidine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonidine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clonidine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Clonidine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clonidine.Approved, Illicit, Withdrawn
FenoldopamClonidine may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clonidine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidClonidine may increase the hypotensive activities of Ferulic acid.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Clonidine.Approved, Investigational
FingolimodClonidine may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Clonidine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Clonidine.Experimental
FluconazoleThe metabolism of Clonidine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clonidine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clonidine.Approved, Illicit
FluoxetineThe metabolism of Clonidine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clonidine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clonidine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clonidine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clonidine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Clonidine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Clonidine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clonidine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clonidine.Approved
FosphenytoinThe metabolism of Clonidine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clonidine.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Clonidine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Clonidine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Clonidine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clonidine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Clonidine is combined with Gabapentin Enacarbil.Approved
GalantamineClonidine may increase the bradycardic activities of Galantamine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clonidine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Clonidine.Investigational
GitoformateClonidine may increase the atrioventricular blocking (AV block) activities of Gitoformate.Experimental
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clonidine.Approved, Illicit
GuanabenzClonidine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelClonidine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineClonidine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineClonidine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Clonidine is combined with Guanfacine.Approved, Investigational
GuanoclorClonidine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzClonidine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanClonidine may increase the hypotensive activities of Guanoxan.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clonidine.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Clonidine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clonidine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Clonidine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Clonidine.Approved, Illicit, Investigational
HexamethoniumClonidine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clonidine.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Clonidine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Clonidine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneClonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideClonidine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clonidine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
IdelalisibThe serum concentration of Clonidine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Clonidine is combined with Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Clonidine.Approved, Investigational
ImatinibThe metabolism of Clonidine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Clonidine.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Clonidine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Clonidine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Indapamide.Approved
IndenololClonidine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Clonidine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Clonidine.Investigational
IndoraminClonidine may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Clonidine.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Clonidine.Experimental
IproclozideIproclozide may increase the hypotensive activities of Clonidine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Clonidine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Clonidine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Clonidine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clonidine.Approved, Vet Approved
IsoniazidThe metabolism of Clonidine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Clonidine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clonidine.Approved
ItraconazoleThe metabolism of Clonidine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineClonidine may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Clonidine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clonidine.Approved, Vet Approved
KetanserinClonidine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clonidine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clonidine.Approved, Investigational
KetoconazoleThe metabolism of Clonidine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolClonidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineClonidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideClonidine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clonidine.Approved, Investigational
Lanatoside CClonidine may increase the atrioventricular blocking (AV block) activities of Lanatoside C.Experimental
LandiololClonidine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LanreotideClonidine may increase the bradycardic activities of Lanreotide.Approved
LatanoprostClonidine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineClonidine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Clonidine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Clonidine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clonidine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levocetirizine.Approved
LevodopaClonidine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clonidine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Clonidine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clonidine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Clonidine.Approved, Investigational
LidocaineThe metabolism of Clonidine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinsidomineClonidine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Clonidine.Approved
LobeglitazoneThe metabolism of Clonidine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Clonidine.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Clonidine.Experimental
LofexidineClonidine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Clonidine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Clonidine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clonidine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clonidine.Approved
LorcaserinThe metabolism of Clonidine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Clonidine.Approved
LosartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Losartan.Approved
LovastatinThe metabolism of Clonidine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clonidine.Approved
LucinactantClonidine may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Clonidine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Clonidine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Clonidine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine.Approved
MacitentanClonidine may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Vet Approved
ManidipineClonidine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Clonidine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Clonidine is combined with Maprotiline.Approved
MebanazineMebanazine may increase the hypotensive activities of Clonidine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Clonidine.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Clonidine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Clonidine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clonidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clonidine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clonidine.Approved, Investigational
MepindololClonidine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonidine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clonidine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Clonidine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clonidine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Clonidine is combined with Metaxalone.Approved
MethadoneThe metabolism of Clonidine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Clonidine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clonidine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clonidine.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonidine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clonidine.Approved
MethoserpidineClonidine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineClonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clonidine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Clonidine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clonidine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Clonidine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clonidine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Clonidine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive activities of Clonidine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clonidine.Approved
MetildigoxinClonidine may increase the atrioventricular blocking (AV block) activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Clonidine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Clonidine.Approved
MetoprololClonidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineClonidine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Clonidine can be decreased when combined with Mexiletine.Approved
MianserinThe therapeutic efficacy of Clonidine can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilClonidine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clonidine.Approved, Illicit
MidostaurinThe metabolism of Clonidine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Clonidine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Clonidine.Approved
MinaprineMinaprine may increase the hypotensive activities of Clonidine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clonidine.Approved
MirabegronThe metabolism of Clonidine can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Clonidine.Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Clonidine.Approved
MitotaneThe serum concentration of Clonidine can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Clonidine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clonidine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Clonidine.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clonidine.Approved, Investigational
MoxonidineClonidine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineClonidine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved, Investigational
NadololClonidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NaftopidilClonidine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clonidine.Approved
NebivololClonidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Clonidine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Clonidine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Clonidine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Clonidine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Clonidine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Clonidine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Clonidine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Clonidine is combined with Nifedipine.Approved
NiguldipineClonidine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Clonidine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineClonidine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clonidine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clonidine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clonidine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Clonidine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Clonidine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Clonidine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Clonidine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clonidine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Clonidine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Clonidine.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Clonidine.Approved
ObinutuzumabClonidine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Clonidine.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Clonidine.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonidine.Approved, Investigational
OlaparibThe metabolism of Clonidine can be decreased when combined with Olaparib.Approved
OleandrinClonidine may increase the atrioventricular blocking (AV block) activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clonidine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Clonidine is combined with Olopatadine.Approved
OmapatrilatClonidine may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clonidine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Clonidine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Clonidine.Approved, Illicit
OrphenadrineClonidine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clonidine.Investigational
OsimertinibThe serum concentration of Clonidine can be increased when it is combined with Osimertinib.Approved
OuabainClonidine may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clonidine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Clonidine.Approved, Investigational
OxprenololClonidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clonidine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clonidine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clonidine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clonidine.Approved, Vet Approved
PalbociclibThe serum concentration of Clonidine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clonidine.Approved
PanobinostatThe serum concentration of Clonidine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Clonidine is combined with Papaverine.Approved
ParaldehydeClonidine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Clonidine.Approved
ParoxetineThe metabolism of Clonidine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideClonidine may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Clonidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololClonidine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Clonidine.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clonidine.Approved, Vet Approved
PentobarbitalThe metabolism of Clonidine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumClonidine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Clonidine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Clonidine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clonidine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clonidine.Approved
PeruvosideClonidine may increase the atrioventricular blocking (AV block) activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clonidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Clonidine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Clonidine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Clonidine.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Clonidine.Withdrawn
PhenobarbitalThe metabolism of Clonidine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Clonidine.Experimental
PhenoxybenzamineClonidine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Clonidine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Clonidine.Withdrawn
PhentolamineClonidine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe metabolism of Clonidine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Clonidine.Approved
PinacidilClonidine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololClonidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clonidine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Clonidine.Investigational
PirlindolePirlindole may increase the hypotensive activities of Clonidine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Clonidine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Clonidine is combined with Pizotifen.Approved
Platelet Activating FactorClonidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PolythiazideClonidine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Clonidine is combined with Pomalidomide.Approved
Poractant alfaClonidine may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Clonidine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololClonidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleClonidine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clonidine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clonidine.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Clonidine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clonidine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Clonidine.Approved
PrimidoneThe metabolism of Clonidine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clonidine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Clonidine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonidine.Approved, Vet Approved
PromazineThe metabolism of Clonidine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Promethazine.Approved
PropafenoneClonidine may increase the bradycardic activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Clonidine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clonidine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clonidine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Clonidine.Approved
PropranololClonidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProscillaridinClonidine may increase the atrioventricular blocking (AV block) activities of Proscillaridin.Experimental
ProtriptylineProtriptyline may decrease the antihypertensive activities of Clonidine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Clonidine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Clonidine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clonidine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Clonidine is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Clonidine can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Clonidine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Clonidine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Clonidine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Clonidine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Clonidine.Approved
RanolazineThe serum concentration of Clonidine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Clonidine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonidine.Approved
RemikirenClonidine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clonidine.Approved, Withdrawn
RescinnamineClonidine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clonidine.Approved, Investigational
RifabutinThe metabolism of Clonidine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Clonidine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Clonidine can be increased when combined with Rifapentine.Approved
RilmenidineClonidine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Clonidine is combined with Riociguat.Approved
RisperidoneClonidine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Clonidine.Investigational
RitonavirThe metabolism of Clonidine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabClonidine may increase the hypotensive activities of Rituximab.Approved
RivastigmineClonidine may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Clonidine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clonidine.Vet Approved
RopiniroleClonidine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonidine.Approved
RotigotineClonidine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clonidine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Clonidine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Clonidine.Approved
SafrazineSafrazine may increase the hypotensive activities of Clonidine.Withdrawn
SaprisartanClonidine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Clonidine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Clonidine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clonidine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Clonidine.Approved, Investigational, Vet Approved
SelexipagClonidine may increase the hypotensive activities of Selexipag.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Clonidine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clonidine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Clonidine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clonidine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Clonidine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Clonidine.Approved
SiltuximabThe serum concentration of Clonidine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Clonidine can be increased when it is combined with Simeprevir.Approved
SitaxentanClonidine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Clonidine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
SotalolClonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilClonidine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Clonidine.Approved
St. John's WortThe serum concentration of Clonidine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Clonidine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Clonidine.Approved, Investigational
SufentanilClonidine may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Clonidine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clonidine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Clonidine.Experimental
SuvorexantClonidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TadalafilTadalafil may increase the antihypertensive activities of Clonidine.Approved, Investigational
TalinololClonidine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Clonidine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Clonidine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Clonidine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Clonidine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Clonidine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Clonidine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clonidine.Approved
TemocaprilClonidine may increase the hypotensive activities of Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Clonidine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Clonidine is combined with Terazosin.Approved
TerbinafineThe metabolism of Clonidine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Clonidine can be decreased when it is combined with Teriflunomide.Approved
TerlipressinClonidine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TertatololClonidine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clonidine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clonidine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clonidine.Investigational
ThalidomideClonidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineClonidine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Clonidine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clonidine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clonidine.Approved, Vet Approved
ThioridazineThe metabolism of Clonidine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clonidine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Clonidine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Clonidine.Approved, Investigational
TiboloneClonidine may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Clonidine can be decreased when combined with Ticlopidine.Approved
TicrynafenClonidine may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clonidine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Clonidine.Experimental
TimololClonidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TipranavirThe metabolism of Clonidine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Clonidine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Clonidine.Approved, Investigational
TolazolineClonidine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clonidine.Approved, Withdrawn
TolonidineClonidine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Clonidine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clonidine.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Clonidine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonidine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clonidine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clonidine.Experimental
TranylcypromineThe metabolism of Clonidine can be decreased when combined with Tranylcypromine.Approved
TravoprostClonidine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Clonidine.Approved, Investigational
TreprostinilClonidine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Clonidine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Clonidine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clonidine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Clonidine.Vet Approved
TrichlormethiazideClonidine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Clonidine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clonidine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Clonidine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clonidine.Approved, Vet Approved
TrimazosinClonidine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanClonidine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineTrimipramine may decrease the antihypertensive activities of Clonidine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clonidine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Clonidine.Approved, Investigational
UnoprostoneClonidine may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may decrease the vasoconstricting activities of Clonidine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clonidine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Clonidine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Clonidine.Approved
VemurafenibThe serum concentration of Clonidine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Clonidine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Clonidine.Experimental
VerapamilClonidine may increase the atrioventricular blocking (AV block) activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Clonidine is combined with Vigabatrin.Approved
VincamineClonidine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineClonidine may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Clonidine.Experimental
VoriconazoleThe metabolism of Clonidine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clonidine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Clonidine.Experimental
XipamideClonidine may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clonidine.Vet Approved
XylometazolineClonidine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Clonidine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clonidine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Clonidine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Clonidine can be decreased when combined with Ziprasidone.Approved
ZofenoprilClonidine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clonidine.Vet Approved
ZolpidemClonidine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Clonidine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clonidine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clonidine.Approved, Investigational
ZucapsaicinThe metabolism of Clonidine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonidine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

David R. Pierce, William D. Dean, Michael E. Deason, "Process for preparation of clonidine derivatives." U.S. Patent US5684156, issued October, 1968.

US5684156
General References
  1. Schapiro NA: "Dude, you don't have Tourette's:" Tourette's syndrome, beyond the tics. Pediatr Nurs. 2002 May-Jun;28(3):243-6, 249-53. [PubMed:12087644]
  2. Hossmann V, Maling TJ, Hamilton CA, Reid JL, Dollery CT: Sedative and cardiovascular effects of clonidine and nitrazepam. Clin Pharmacol Ther. 1980 Aug;28(2):167-76. [PubMed:7398184]
External Links
Human Metabolome Database
HMDB14714
KEGG Drug
D00281
PubChem Compound
2803
PubChem Substance
46508119
ChemSpider
2701
BindingDB
14062
ChEBI
46632
ChEMBL
CHEMBL134
Therapeutic Targets Database
DAP000231
PharmGKB
PA449051
IUPHAR
516
Guide to Pharmacology
GtP Drug Page
HET
CLU
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Clonidine
ATC Codes
S01EA04 — ClonidineN02CX02 — ClonidineC02LC01 — Clonidine and diureticsC02AC01 — ClonidineC02LC51 — Clonidine and diuretics, combinations with other drugs
AHFS Codes
  • 24:08.16 — Central Alpha-agonists
PDB Entries
2pnc
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentBlood Pressures / Hypertensive1
1CompletedBasic ScienceAmphetamine-Related Disorders / Moods Disorders / Substance-Related Disorders1
1CompletedTreatmentCocaine Abuse / Heroin Abuse1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHypertensive1
1CompletedTreatmentOpioid-Related Disorders1
1RecruitingTreatmentCutaneous Nerves CNS Itch1
1RecruitingTreatmentHypoxic Ischemic Encephalopathy (HIE)1
1, 2Active Not RecruitingTreatmentChronic Orthostatic Intolerance / Tachycardia1
1, 2CompletedPreventionPost Operative Pain1
1, 2CompletedTreatmentHypoxic-Ischaemic Encephalopathy1
1, 2CompletedTreatmentOpioid Addiction / Opioid Dependence / Opioid Related Disorders1
1, 2CompletedTreatmentPain, Acute / Respiration stimulated / Sedation therapy1
1, 2CompletedTreatmentPostoperative pain1
1, 2RecruitingTreatmentMechanical Ventilation Complication1
1, 2TerminatedTreatmentPain1
1, 2WithdrawnTreatmentHypertensive / Pregnancy Toxemias / Proteinuria1
1, 2WithdrawnTreatmentTreatment-Related Cancer1
2CompletedSupportive CareCholesteatoma / Cochlear Implants / Mastoidectomy / Tympanomastoid Surgery1
2CompletedSupportive CarePostoperative pain1
2CompletedTreatmentAnaesthesia therapy2
2CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
2CompletedTreatmentDiabetes / Painful Diabetic Neuropathy1
2CompletedTreatmentDiabetic Neuropathies / Neuropathy / Painful Diabetic Neuropathy2
2CompletedTreatmentDrug withdrawal syndrome neonatal1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentHydrocele / Inguinal Hernias1
2CompletedTreatmentHypertensive1
2CompletedTreatmentIncontinence, Fecal1
2CompletedTreatmentMyalgic Encephalomyelitis (ME)1
2CompletedTreatmentOpioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentPain2
2CompletedTreatmentPainful Diabetic Neuropathy1
2RecruitingSupportive CareCancer, Breast / Menopausal Hot Flushes1
2RecruitingTreatmentBMI >30 kg/m2 / Hypertensive / Prehypertension1
2RecruitingTreatmentDelirium1
2TerminatedTreatmentVasospasm1
2Unknown StatusTreatmentArrythmias / Pain1
2Unknown StatusTreatmentFeeling Anxious1
2WithdrawnTreatmentAutism Spectrum Conditions/Disorders1
2WithdrawnTreatmentOther Reconstructive Surgery1
2, 3CompletedTreatmentMinor burns1
2, 3RecruitingPreventionTransversus Abdominis Plane Block / Transversus Abdominis Plane Block, Pediatric Laparoscopy1
2, 3RecruitingTreatmentCannabis Dependence / Marijuana Dependence1
2, 3RecruitingTreatmentDrug Dependence1
2, 3TerminatedDiagnosticShock, Septic1
2, 3TerminatedTreatmentDrug withdrawal syndrome neonatal1
3CompletedPreventionCardiovascular Disease (CVD)1
3CompletedPreventionIs an Only Child1
3CompletedPreventionNegative Behaviour Change1
3CompletedPreventionNormal Pregnancies1
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
3CompletedTreatmentBiceps Tendonitis1
3CompletedTreatmentHyperemesis Gravidarum1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentUpper Extremity Fractures1
3Not Yet RecruitingTreatmentDelirium1
3RecruitingSupportive CareIntraoperative Neurophysiological Monitoring / Pain Management1
3RecruitingSupportive CareMalignant Neoplasms of Male Genital Organs1
3RecruitingTreatmentBile Acid Malabsorption / Incontinence, Fecal1
3RecruitingTreatmentLocoregional Analgesia / Neoplasms, Breast1
3RecruitingTreatmentPain1
3RecruitingTreatmentSedation in Intensive Care1
3RecruitingTreatmentLumbar epidural anesthesia therapy1
3TerminatedTreatmentPain1
3Unknown StatusTreatmentDiabetic Neuropathies / Pain1
3WithdrawnTreatmentPostoperative Hyperalgesia1
4Active Not RecruitingTreatmentInguinal Hernias / Spinal Anaesthesia1
4CompletedBasic ScienceHeart Failure, Unspecified1
4CompletedPreventionPsychomotor Agitation1
4CompletedTreatmentAnalgesia / Pain / Systemic Inflammatory Stress Response1
4CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
4CompletedTreatmentCritical Illness / Deep Sedation / Respiration, Artificial / Sedation, Conscious1
4CompletedTreatmentDelirium1
4CompletedTreatmentGilles de la Tourette's Syndrome / Tic Disorders1
4CompletedTreatmentGlycemia During Coronary Artery Bypass Graft / Sedation During Pre-anesthetic Medication1
4CompletedTreatmentHypertensive2
4CompletedTreatmentLabour1
4CompletedTreatmentLocal Anesthesia1
4CompletedTreatmentOpiate withdrawal symptoms / Opioid-use Disorder1
4CompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
4CompletedTreatmentPost-Operative Pain1
4CompletedTreatmentPreeclampsia1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4Enrolling by InvitationTreatmentKnee Osteoarthritis (Knee OA)1
4Enrolling by InvitationTreatmentTotal Hip Arthroplasty (THA)1
4Not Yet RecruitingTreatmentDrug withdrawal syndrome neonatal1
4RecruitingBasic ScienceFeeling Anxious / Hypertensive1
4RecruitingPreventionPostoperative pain1
4RecruitingTreatmentAcetabular Labrum Tear / Femoroacetabular Impingement / Hip Dysplasia1
4RecruitingTreatmentLabour Pain2
4RecruitingTreatmentOpiate withdrawal symptoms1
4RecruitingTreatmentPostoperative pain2
4TerminatedTreatmentBipolar Disorder, Mania1
4Unknown StatusDiagnosticAtaxia Telangiectasia (AT) / Growth Failure1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusPreventionHeart Diseases1
4Unknown StatusTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Gilles de la Tourette's Syndrome1
4Unknown StatusTreatmentDrug withdrawal syndrome neonatal1
4Unknown StatusTreatmentHypertensive1
4Unknown StatusTreatmentNeonates / Spinal Anaesthesia1
4Unknown StatusTreatmentPatients to Benefit a Planned Femoropopliteal Bypass Through PAOD (Peripheral Arterial Occlusive Disease) Stage II or III1
4WithdrawnPreventionKnee Arthroscopy / Shoulder Arthroscopy1
4WithdrawnSupportive CarePain Management / Total Knee Arthroplasty (TKA)1
4WithdrawnTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedNot AvailableKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedNot AvailableLabour Pain1
Not AvailableCompletedNot AvailableMyalgic Encephalomyelitis (ME)1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedNot AvailableSedation therapy1
Not AvailableCompletedBasic ScienceIntrusive Memories1
Not AvailableCompletedPreventionSecondary Hyperalgesia1
Not AvailableCompletedSupportive CareComplex Regional Pain Syndrome (CRPS)1
Not AvailableCompletedSupportive CareFeeling Anxious / Pain1
Not AvailableCompletedSupportive CareOsteoarthritis (OA) / Post-traumatic; Arthrosis1
Not AvailableCompletedTreatmentAscitic Cirrhosis / Hyperactivation of Sympathetic Nervous System1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentOpiate Addiction1
Not AvailableCompletedTreatmentPregnancy1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableEnrolling by InvitationNot AvailableCardiovascular Disease (CVD) / Cardiovascular Risk Factors / Hypertensive / Mental status changes / Sleep Apnea Syndrome / Sleep Bruxism / Sleep disorders and disturbances / Temporomandibular Disorders / Thyroid Dysfunction1
Not AvailableRecruitingTreatmentDepressive Disorder, Treatment-Resistant1
Not AvailableRecruitingTreatmentPostoperative pain1
Not AvailableRecruitingTreatmentRenal Dialysis1
Not AvailableRecruitingTreatmentSubstance Withdrawal Syndrome1
Not AvailableTerminatedTreatmentBack Pain1
Not AvailableTerminatedTreatmentDrug withdrawal syndrome neonatal1
Not AvailableTerminatedTreatmentFeeling Anxious / Pain1
Not AvailableTerminatedTreatmentLumbar and Other Intervertebral Disc Disorders With Radiculopathy1
Not AvailableTerminatedTreatmentVentricular Tachycardia (VT)1
Not AvailableWithdrawnBasic ScienceExperimental Pain Perception1
Not AvailableWithdrawnTreatmentFull Term Pregnant Patients / Undergoing Lower Segment Caesarian Section1

Pharmacoeconomics

Manufacturers
  • Boehringer ingelheim
  • Aveva drug delivery systems inc
  • Mylan technologies inc
  • Tris pharma inc
  • Pharmaforce inc
  • Bioniche pharma usa llc
  • Actavis elizabeth llc
  • American therapeutics inc
  • Dava pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Impax laboratories inc
  • Interpharm inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Unichem laboratories ltd
  • Vintage pharmaceuticals llc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Shionogi pharma inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionEpidural100 ug/mL
Injection, solutionEpidural500 ug/mL
PatchTransdermal.1 mg/d
PatchTransdermal.2 mg/d
PatchTransdermal.3 mg/d
Patch, extended releaseTransdermal.1 mg/24h
Patch, extended releaseTransdermal.2 mg/24h
Patch, extended releaseTransdermal.3 mg/24h
TabletOral.2 mg
Injection, solutionIntravenous100 ug/mL
Injection, solutionIntravenous500 ug/mL
TabletOral.1 mg/1
TabletOral.2 mg/1
TabletOral.3 mg/1
Tablet, extended releaseOral.1 mg/1
TabletOral
Injection, solutionEpidural.1 mg/mL
Injection, solutionEpidural.5 mg/mL
Tablet, extended releaseOral.2 mg/1
Tablet, extended releaseOral.17 mg/1
For suspension, extended releaseOral.09 mg/mL
Tablet, extended releaseOral.26 mg/1
TabletOral.1 mg
TabletOral0.025 mg
TabletOral0.1 mg
TabletOral0.2 mg
Prices
Unit descriptionCostUnit
Catapres-TTS-3 4 0.3 mg/24hr Patches Box328.42USD box
CloNIDine HCl 4 0.3 mg/24hr Patches Box279.9USD box
Catapres-TTS-2 4 0.2 mg/24hr Patches Box236.75USD box
CloNIDine HCl 4 0.2 mg/24hr Patches Box201.75USD box
Catapres-TTS-1 4 0.1 mg/24hr Patches Box141.08USD box
CloNIDine HCl 4 0.1 mg/24hr Patches Box119.84USD box
Catapres-tts 3 patch78.95USD patch
Clonidine 0.3 mg/day patch67.28USD patch
Clonidine hcl powder53.09USD g
Clonidine 0.2 mg/day patch48.5USD patch
Duraclon 500 mcg/ml vial47.4USD ml
Catapres-tts 2 patch39.23USD patch
Clonidine 0.1 mg/day patch28.81USD patch
Catapres-tts 1 patch21.18USD patch
Clonidine 5000 mcg/10 ml vial21.0USD ml
Duraclon 0.1 mg/ml vial14.4USD ml
Clonidine 1000 mcg/10 ml vial5.04USD ml
Catapres 0.3 mg tablet2.98USD tablet
Catapres 0.2 mg tablet2.35USD tablet
Catapres 0.1 mg tablet1.57USD tablet
Clonidine hcl 0.3 mg tablet0.5USD tablet
Clonidine hcl 0.2 mg tablet0.35USD tablet
Catapres 0.2 mg Tablet0.35USD tablet
Apo-Clonidine 0.2 mg Tablet0.33USD tablet
Novo-Clonidine 0.2 mg Tablet0.33USD tablet
Nu-Clonidine 0.2 mg Tablet0.33USD tablet
Dixarit 0.025 mg Tablet0.28USD tablet
Clonidine hcl 0.1 mg tablet0.24USD tablet
Catapres 0.1 mg Tablet0.19USD tablet
Apo-Clonidine 0.1 mg Tablet0.18USD tablet
Novo-Clonidine 0.1 mg Tablet0.18USD tablet
Nu-Clonidine 0.1 mg Tablet0.18USD tablet
Apo-Clonidine 0.025 mg Tablet0.16USD tablet
Novo-Clonidine 0.025 mg Tablet0.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5869100No1993-10-132013-10-13Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)3053,202,660
water solubilityAppreciableNot Available
logP1.59HANSCH,C & LEO,AJ (1985)
Caco2 permeability-4.59ADME Research, USCD
pKa8.05 (at 25 °C)KONTTURI,K & MURTOMAKI,L (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.48 mg/mLALOGPS
logP2.55ALOGPS
logP2.49ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area36.42 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity59.09 m3·mol-1ChemAxon
Polarizability21.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9632
Blood Brain Barrier+0.9402
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6305
P-glycoprotein inhibitor INon-inhibitor0.9061
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.745
CYP450 2C9 substrateNon-substrate0.8219
CYP450 2D6 substrateNon-substrate0.6984
CYP450 3A4 substrateNon-substrate0.6353
CYP450 1A2 substrateNon-inhibitor0.8998
CYP450 2C9 inhibitorNon-inhibitor0.7681
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.8732
CYP450 3A4 inhibitorNon-inhibitor0.8332
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.803
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9303
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity3.5030 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7232
hERG inhibition (predictor II)Non-inhibitor0.8905
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-003r-5970000000-33c27878b8b7ad9d5d75
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0090000000-2c051509a637beaafe73
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0090000000-f1477af875c25c537ccb
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0090000000-ccdeb1dfce0424b12c0c
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-01po-6950000000-dd68628a46215027ef29
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-6900000000-ce531320f1fda74d127e
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-03fr-2980000000-24b18e2a89a65b2b178f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0190000000-7cbbf9fb244993abe922

Taxonomy

Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Aniline and substituted anilines / Aryl chlorides / Imidazolines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
1,3-dichlorobenzene / Aniline or substituted anilines / Aryl chloride / Aryl halide / 2-imidazoline / Guanidine / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
clonidine (CHEBI:3757)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL: alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 2002 Jan;300(1):282-90. [PubMed:11752127]
  2. Lavand'homme PM, Ma W, De Kock M, Eisenach JC: Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology. 2002 Oct;97(4):972-80. [PubMed:12357167]
  3. Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M: The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol. 2004 Aug 23;497(2):161-71. [PubMed:15306201]
  4. Ozdogan UK, Lahdesmaki J, Mansikka H, Scheinin M: Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur J Pharmacol. 2004 Feb 6;485(1-3):193-6. [PubMed:14757140]
  5. Wang XM, Zhang ZJ, Bains R, Mokha SS: Effect of antisense knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. Pain. 2002 Jul;98(1-2):27-35. [PubMed:12098614]
  6. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Hein, L. (2004). alpha-Adrenergic system. In Encyclopedic reference of molecular pharmacology (pp. 27-30). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. PDSP Ki Database [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Claessens AJ, Risler LJ, Eyal S, Shen DD, Easterling TR, Hebert MF: CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. doi: 10.1124/dmd.110.033878. Epub 2010 Jun 22. [PubMed:20570945]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Bednarczyk D, Ekins S, Wikel JH, Wright SH: Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98. [PubMed:12606755]
  2. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257]
  3. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
  4. Martel F, Vetter T, Russ H, Grundemann D, Azevedo I, Koepsell H, Schomig E: Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):320-6. [PubMed:8878062]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924]
  2. Martel F, Grundemann D, Calhau C, Schomig E: Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters. Naunyn Schmiedebergs Arch Pharmacol. 2001 Jan;363(1):40-9. [PubMed:11191835]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
  2. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34